BR9508991A - Compound process for the preparation of a compound pharmaceutical composition process for the treatment of hyperglycemia obesity arteriosclerosis hyperinsulinemia gastrointestinal disorders or the treatment of gastrointestinal ulcerations in a human or non-human mammal process to increase weight gain and / or improve the efficiency of the use of feeding and / or increasing the body mass curve and / or decreasing the birth mortality rate and increasing the postnatal survival rate of farm animals and veterinarily acceptable pre-mix formulation - Google Patents

Compound process for the preparation of a compound pharmaceutical composition process for the treatment of hyperglycemia obesity arteriosclerosis hyperinsulinemia gastrointestinal disorders or the treatment of gastrointestinal ulcerations in a human or non-human mammal process to increase weight gain and / or improve the efficiency of the use of feeding and / or increasing the body mass curve and / or decreasing the birth mortality rate and increasing the postnatal survival rate of farm animals and veterinarily acceptable pre-mix formulation

Info

Publication number: BR9508991A
Authority: BR; Brazil
Prior art keywords: increasing; treatment; compound; human; gastrointestinal
Prior art date: 1994-07-29

Application number

BR9508991A

Other languages

Portuguese (pt)

Inventor

Lee James Beeley

Mervyn Thompson

David Kenneth Dean

Nikesh Rasiklal Kotecha

John Michael Berge

Robert William Ward

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-29

Filing date

1995-07-27

Publication date

1997-10-21

1994-07-29 Priority claimed from GB9415304A external-priority patent/GB9415304D0/en

1994-11-17 Priority claimed from GB9423179A external-priority patent/GB9423179D0/en

1995-05-24 Priority claimed from GBGB9510485.7A external-priority patent/GB9510485D0/en

1995-07-27 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1997-10-21 Publication of BR9508991A publication Critical patent/BR9508991A/en

Links

238000000034 method Methods 0.000 title 3
150000001875 compounds Chemical class 0.000 title 2
206010003210 Arteriosclerosis Diseases 0.000 title 1
208000018522 Gastrointestinal disease Diseases 0.000 title 1
206010060378 Hyperinsulinaemia Diseases 0.000 title 1
241001465754 Metazoa Species 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
208000025865 Ulcer Diseases 0.000 title 1
208000011775 arteriosclerosis disease Diseases 0.000 title 1
UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 title 1
230000003247 decreasing effect Effects 0.000 title 1
238000009472 formulation Methods 0.000 title 1
230000002496 gastric effect Effects 0.000 title 1
201000001421 hyperglycemia Diseases 0.000 title 1
230000003451 hyperinsulinaemic effect Effects 0.000 title 1
201000008980 hyperinsulinism Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000004083 survival effect Effects 0.000 title 1
230000036269 ulceration Effects 0.000 title 1
230000004584 weight gain Effects 0.000 title 1
235000019786 weight gain Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/303—Cycloaliphatic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3223—Esters of cycloaliphatic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BR9508991A 1994-07-29 1995-07-27 Compound process for the preparation of a compound pharmaceutical composition process for the treatment of hyperglycemia obesity arteriosclerosis hyperinsulinemia gastrointestinal disorders or the treatment of gastrointestinal ulcerations in a human or non-human mammal process to increase weight gain and / or improve the efficiency of the use of feeding and / or increasing the body mass curve and / or decreasing the birth mortality rate and increasing the postnatal survival rate of farm animals and veterinarily acceptable pre-mix formulation BR9508991A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB9415304A GB9415304D0 (en)	1994-07-29	1994-07-29	Novel compounds
GB9423179A GB9423179D0 (en)	1994-11-17	1994-11-17	Novel compounds
GBGB9510485.7A GB9510485D0 (en)	1995-05-24	1995-05-24	Novel compounds
PCT/EP1995/003037 WO1996004233A1 (en)	1994-07-29	1995-07-27	Aryloxy and arylthiopropanolamine derivatives useful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof

Publications (1)

Publication Number	Publication Date
BR9508991A true BR9508991A (en)	1997-10-21

Family

ID=27267307

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9508991A BR9508991A (en)	1994-07-29	1995-07-27	Compound process for the preparation of a compound pharmaceutical composition process for the treatment of hyperglycemia obesity arteriosclerosis hyperinsulinemia gastrointestinal disorders or the treatment of gastrointestinal ulcerations in a human or non-human mammal process to increase weight gain and / or improve the efficiency of the use of feeding and / or increasing the body mass curve and / or decreasing the birth mortality rate and increasing the postnatal survival rate of farm animals and veterinarily acceptable pre-mix formulation

Country Status (12)

Country	Link
EP (1)	EP0772585A1 (en)
JP (1)	JPH10503507A (en)
CN (1)	CN1159797A (en)
AU (1)	AU3254695A (en)
BR (1)	BR9508991A (en)
CA (1)	CA2196193A1 (en)
CZ (1)	CZ25597A3 (en)
HU (1)	HUT76800A (en)
MX (1)	MX9700765A (en)
NO (1)	NO970372L (en)
PL (1)	PL318381A1 (en)
WO (1)	WO1996004233A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9605495D0 (en) *	1996-03-15	1996-05-15	Smithkline Beecham Plc	Novel compounds
US5914339A (en) *	1996-05-14	1999-06-22	American Home Products Corporation	Substituted 1,3-benzodioxoles
ES2171839T3 (en) *	1996-09-05	2002-09-16	Lilly Co Eli	CARBAZOL ANALOGS AS BETA3 SELECTIVE ADRENERGIC AGONISTS.
WO1998022480A1 (en) *	1996-11-18	1998-05-28	Smithkline Beecham Plc	Phosphorus containing aryloxy or arylthio propanolamine derivatives
GB9703492D0 (en) *	1997-02-20	1997-04-09	Smithkline Beecham Plc	Novel compounds
CO5011072A1 (en) *	1997-12-05	2001-02-28	Lilly Co Eli	ETANOLAMINAS PIRAZINIL SUBSTITUTED AS AGFONISTS OF THE RECEPTORS
DE69928185T2 (en) *	1998-01-30	2006-07-20	Boulder Scientific Co., Mead	SYNTHESIS OF N-SILYLATED COMPOUNDS
DE69940484D1 (en)	1998-04-06	2009-04-09	Astellas Pharma Inc	Use of beta-3 adrenergic receptor agonists in the treatment of dysuria
AUPP549998A0 (en) *	1998-08-26	1998-09-17	Fujisawa Pharmaceutical Co., Ltd.	New compound
US7098248B2 (en)	2001-07-09	2006-08-29	Research Development Foundation	Beta-adrenergic blockade reversal of catabolism after severe burn
DE102008064003A1 (en) *	2008-12-19	2010-06-24	Clariant International Limited	Process for the preparation of monofunctionalized dialkylphosphinic acids, esters and salts and their use
CN107266341B (en) *	2017-06-23	2020-01-07	华东师范大学	Aryloxy substituted propan-2-ol amine derivative as beta3 adrenergic receptor antagonist, preparation method and application
CN112442167A (en) *	2019-08-28	2021-03-05	广东广山新材料股份有限公司	Reactive flame retardant and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1262729A (en) *	1983-10-19	1989-11-07	Leo Alig	Phenoxypropanolamines
EP0300290B1 (en) *	1987-07-21	1991-12-18	F. Hoffmann-La Roche Ag	Phenoxypropanol amines
GB8801306D0 (en) *	1988-01-21	1988-02-17	Ici Plc	Chemical compounds
GB9215844D0 (en) *	1992-07-25	1992-09-09	Smithkline Beecham Plc	Novel compounds

1995
- 1995-07-27 AU AU32546/95A patent/AU3254695A/en not_active Abandoned
- 1995-07-27 BR BR9508991A patent/BR9508991A/en not_active Application Discontinuation
- 1995-07-27 HU HU9700262A patent/HUT76800A/en unknown
- 1995-07-27 WO PCT/EP1995/003037 patent/WO1996004233A1/en not_active Application Discontinuation
- 1995-07-27 PL PL95318381A patent/PL318381A1/en unknown
- 1995-07-27 EP EP95929029A patent/EP0772585A1/en not_active Withdrawn
- 1995-07-27 CA CA002196193A patent/CA2196193A1/en not_active Abandoned
- 1995-07-27 MX MX9700765A patent/MX9700765A/en unknown
- 1995-07-27 CN CN95195371A patent/CN1159797A/en active Pending
- 1995-07-27 CZ CZ97255A patent/CZ25597A3/en unknown
- 1995-07-27 JP JP8506193A patent/JPH10503507A/en active Pending
1997
- 1997-01-28 NO NO970372A patent/NO970372L/en unknown

Also Published As

Publication number	Publication date
NO970372D0 (en)	1997-01-28
EP0772585A1 (en)	1997-05-14
CA2196193A1 (en)	1996-02-15
CZ25597A3 (en)	1998-02-18
NO970372L (en)	1997-03-18
HUT76800A (en)	1997-11-28
JPH10503507A (en)	1998-03-31
CN1159797A (en)	1997-09-17
PL318381A1 (en)	1997-06-09
AU3254695A (en)	1996-03-04
WO1996004233A1 (en)	1996-02-15
MX9700765A (en)	1997-05-31

Legal Events

Date	Code	Title
2001-07-03	EG	Technical examination (opinion): publication of technical examination (opinion)
2002-05-07	FB36	Technical and formal requirements: requirement - article 36 of industrial property law
2003-05-06	FA8	Dismissal: dismissal - article 36, par. 1 of industrial property law

Publication	Publication Date	Title
BR9508991A (en)	1997-10-21	Compound process for the preparation of a compound pharmaceutical composition process for the treatment of hyperglycemia obesity arteriosclerosis hyperinsulinemia gastrointestinal disorders or the treatment of gastrointestinal ulcerations in a human or non-human mammal process to increase weight gain and / or improve the efficiency of the use of feeding and / or increasing the body mass curve and / or decreasing the birth mortality rate and increasing the postnatal survival rate of farm animals and veterinarily acceptable pre-mix formulation
CN109069475B (en)	2022-01-28	Fast acting botanical pharmaceutical compounds and nutritional supplements
ATE539618T1 (en)	2012-01-15	PET FOOD FOR MAINTAINING BOTH HEALING AND RELIEVING ARTHRITIC SYMPTOMS IN DOGS
JP2006525243A5 (en)	2009-04-02
Dhanalakshmi et al.	2007	Protective effect of Triphala on cold stress-induced behavioral and biochemical abnormalities in rats
US20130142851A1 (en)	2013-06-06	Compositions Comprising Components Coated With a Liquid Impermeable but Gas Permeable Layer, Use Thereof for Treating Cutaneous and Other Exocrine Gland Diseases
WO2006015279A8 (en)	2006-03-16	Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
Tembe-Fokunang et al.	2019	The potential pharmacological and medicinal properties of neem (Azadirachta indica A. Juss) in the drug development of phytomedicine
BR112015020019B1 (en)	2021-05-18	pharmaceutical dosage form and its use
RU2009136424A (en)	2011-04-10	COMPOSITION AND METHOD FOR TREATING PAPILLOMAVIRUS AND HORSE SARCOIDS
Pagan	1997	Gastric ulcers in horses: a widespread but manageable disease
O'LEARY et al.	1953	Quinacrine (Atabrine) hydrochloride in treatment of discoid lupus erythematosus
Jimmy et al.	2020	Aloe Vera Heals Gastric Ulcer in 7 days than Omeprazole and Cimetidine: Prostaglandin
Calhoun et al.	1992	Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat
Carr et al.	2008	Pet pig medicine: 2. The sick pig
Bath	1978	Hexachlorophene toxicity in dogs
Canello et al.	2019	Unraveling a commercial formula to relieve halitosis in dogs
Gould et al.	1985	Indomethacin and 7, 12‐dimethylbenz (a) anthraceneinduced carcinogenesis in the hamster buccal pouch
Solanki et al.	2007	Indigenous knowledge of veterinary medicines among tribals of West Nimar.
Henderson et al.	1984	Maxillary dento-alveolar abscess in a spotted hyaena Crocuta crocuta
Bartels	2002	Studies of local anaesthetics for velvet antler analgesia: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science at Massey University
KR19980043965A (en)	1998-09-05	Comprehensive Kim Ki Pharm and its manufacturing method
Walther	1861	The Horse-owner's Guide: Or, Practical Instructions on the Horseman's Points, the Horse in Health, the Horse in Sickness... Embracing, Also, a Number of the Most Valuable Recipes in Use by the Best European Veterinarians...
Hartley	1918	An outbreak of Phlebotomus fever
ES2517395T3 (en)	2014-11-03	Combination of a centrally acting analgesic and a selective cyclooxygenase-2 inhibitor anti-inflammatory agent for the treatment of inflammation and pain in the veterinary sector